+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768293
  • Report
  • April 2019
  • Region: Global
  • 46 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • ChemoCentryx Inc
  • Galenica Ltd
  • Omeros Corp
  • PSI CRO AG
  • MORE
The global clinical trial report- “2019 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome). It presents in-depth analysis of Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome)

The research work is prepared through extensive and continuous research on Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) patients are identified
  • The report includes panorama of Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • ChemoCentryx Inc
  • Galenica Ltd
  • Omeros Corp
  • PSI CRO AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Region
2.2.2 Average Enrollment of Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Treatment, 2019

3. Region wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
3.1 Asia Pacific Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Country
3.2 Europe Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Country
3.3 North America Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Country
3.4 Middle East and Africa Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Country
3.5 South and Central America Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Country

4. Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trial Trends
4.1 Start Year wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
4.2 Phase wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
4.3 Trial Status wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
4.4 Trial Type wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials

5. Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment Trends
5.1 Average Enrollment in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials by Year
5.2 Average Enrollment in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials by Phase
5.3 Average Enrollment in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials by Status
5.4 Average Enrollment in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials by Type of Trial

6. Companies Participating in Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials
6.1 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials by Sponsor Type
6.2 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials- Phase 1
7.2 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials- Phase 2
7.3 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials- Phase 3
7.4 Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Figure 7: North America - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Figure 9: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Phase
Figure 10: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Trial Status
Figure 11: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Type
Figure 12: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Sponsor Type
Figure 13: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials by Leading Sponsors
Figure 14: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Phase
Figure 15: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Trial Status
Figure 16: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Type
Figure 17: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome)- Average Enrolment by Type of Sponsors
Figure 18: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Table 5: Europe - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Table 7: North America - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Phase
Table 15: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Trial Status
Table 16: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome) Average Enrollment by Type
Table 17: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome)- Average Enrolment by Type of Sponsors
Table 18: Atypical Hemolytic Uremic Syndrome (Nondiarrhea Associated Hemolytic Uremic Syndrome)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Achillion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • ChemoCentryx Inc
  • Galenica Ltd
  • Laboratory Corp of America Holdings
  • Omeros Corp
  • PSI CRO AG
Note: Product cover images may vary from those shown
Adroll
adroll